TABLE 1.

Prescription of lipid-lowering agents 2012–2021 (in DID).

Year	Total	All statin prescriptions	Statin mono	Statin-ezetimibe FDC	Ezetimibe mono	Fibrate mono	PCSK9 inhibitor*	Bempedoic acid#	Other
2012	69.8	66.6	63.9	2.70	0.99	2.10	–	–	0.19
2013	72.6	69.6	67.3	2.34	0.94	1.91	–	–	0.09
2014	74.3	71.6	69.5	2.13	0.94	1.74	–	–	0.09
2015	78.9	76.1	73.9	2.24	1.08	1.63	0.00	–	0.09
2016	83.6	80.7	78.0	2.68	1.25	1.51	0.04	–	0.09
2017	87.0	83.9	80.8	3.03	1.49	1.37	0.09	–	0.10
2018	91.6	88.1	84.9	3.06	2.03	1.25	0.14	–	0.10
2019	98.4	94.2	90.8	3.25	2.68	1.16	0.18	–	0.10
2020	107.2	102.1	98.6	3.40	3.69	1.03	0.21	0.01	0.11
2021	118.2	111.4	107.8	3.47	5.19	0.98	0.29	0.19	0.11

DID, defined daily doses per 1,000 statutory health insurance-insured persons per day; mono, monotherapy; FDC, fixed-dose combinations.

*Includes proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies and inclisiran.

^#Includes monotherapy and bempedoic acid-ezetimibe FDC. Bold denotes the total values.